


PHARMACEUTICAL 2022



MEDICINOVA INC Rank 58 of 475





PHARMACEUTICAL 2022



MEDICINOVA INC Rank 58 of 475



The relative strengths and weaknesses of MEDICINOVA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEDICINOVA INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 87% points. The greatest weakness of MEDICINOVA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 388% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	72,009
Cost of Goods Sold	0
Intangible Assets	9,600
Liabilities, Current	2,833
Liabilities, Non-Current	695
Other Assets	5,740
Other Compr. Net Income	-11
Other Expenses	8,541
Other Liabilities	202
Other Net Income	84
Property and Equipment	58
Research and Development	0
Revenues	4,038
Selling, General and Administrative Expense	5,715

Output Variable	Value in 1000 USD
Assets	87,406
Liabilities	3,729
Expenses	14,256
Stockholders Equity	83,677
Net Income	-10,134
Comprehensive Net Income	-10,140
Economic Capital Ratio	112%